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. Among patients with chronic HCV infection, about 20% of them will evolve to cirrhosis over a period of 20-30 years. Once cirrhosis is established, the annual rates of developing hepatic decompensation and hepatocellular carcinoma (HCC) are 3-6% and 1-4%, respectively 2, 3 . In addition to increasing the risks of liver-related morbidity and mortality, HCV infection is also associated with various extra-hepatic manifestations which further compromised the patients' health outcome and quality of life 4 . On the other hand, the morbidity and mortality are significantly reduced once these patients achieve sustained virologic response (SVR) by anti-HCV agents [5] [6] [7] [8] [9] . The use of interferon (IFN)-free direct acting antiviral agents (DAAs) has made a paradigm shift and become the standard of care for HCV infection. Sofosbuvir (SOF) is a pyrimidine nucleotide analogue that inhibits the HCV non-structural protein 5B (NS5B) ribonucleic acid (RNA)-dependent RNA polymerase, which is essential for viral replication. After intra-hepatic metabolism to active uridine triphosphate form, the GS-461203, it is incorporated to HCV RNA by NS5B polymerase and acts as the chain terminator 10 . Clinically, SOF is administered once-daily with pangenotypic potency, well tolerability, a high genetic barrier to drug resistance, and low rates of drug-drug interactions (DDIs). Furthermore, SOF can be used in combination with various kinds of NS3/4 A protease inhibitors (PIs), NS5A inhibitors, and/or ribavirin (RBV) to achieve high SVR rates [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Because of the excellent therapeutic profiles, treatment of HCV by SOF-based regimens is appealing to most health care providers.
Although SOF-based IFN-free DAAs are highly efficacious and well tolerated, many HCV-infected individuals have limited governmental reimbursement or private insurance support for brand-name agents [24] [25] [26] . Allowing generic SOF-based DAAs through voluntary or compulsory licensing can scale up the HCV treatment to facilitate more efficient HCV control, particularly for patients in resource-constrained countries. Regarding the effectiveness and safety of generic SOF in combination with ledipasvir (LDV), daclatasvir (DCV), and/or RBV, several reports from China, India, Egypt and Argentina indicated that the SVR rates were >90% and most patients tolerated the treatment well [27] [28] [29] [30] [31] . On the basis of these encouraging results, we aimed to evaluate the performance of generic SOF-based DAAs for HCV and factors potentially affecting the treatment response in a multicenter cohort in Taiwan.
Materials and Methods

Patients. Between May 2016 and June 2017, HCV-infected patients who received generic SOF-based IFN-
free therapies for 12 or 24 weeks at the National Taiwan University Hospital (NTUH), NTUH Yun-Lin Branch, Taichung Veterans General Hospital, and Cathay General Hospital Medical Center were retrospectively enrolled. All patients were aged ≥20 years and had chronic HCV infection, defined as detectable HCV antibody (anti-HCV; Abbott HCV EIA 2.0, Abbott Laboratories, Abbott Park, Illinois, USA) and quantifiable serum HCV RNA (Cobas TaqMan HCV Test v2.0, Roche Diagnostics GmbH, Mannheim, Germany, lower limit of detection [LLOD]: 15 IU/mL) for ≥6 months. Patients were excluded from the study if they had a history of DAA exposure, had estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m 2 , had active HCC, received antiviral regimens not recommended by American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA), European Association for the Study of the Liver (EASL) or Asian Pacific Association for the Study of the Liver (APASL) guidelines, or refused to provide written informed consent [32] [33] [34] . The study was approved by the Research Ethics Committee of National Taiwan University Hospital, Taichung Veterans Hospital and Cathay General Hospital and was conducted in accordance with the principles of Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice. All patients provided written informed consent before the study. 35 . The cirrhosis status was determined by liver biopsy, clinical signs of portal hypertension, imaging studies, AST-to-platelet ratio index (ARPI) at a cutoff value of >2.0 or liver stiffness measurement (LSM, FibroScan ® , Echosens, Paris, France) at a cutoff value of >12.5 kPa when appropriate 36 . In cirrhotic patients, the severity was graded by Child-Pugh score. Safety. The rate of treatment completion was assessed for each regimen. The reasons for patients who were lost to follow-up were recorded by the treating physicians. In patients who were seropositive for HBsAg, serum HBV DNA levels were evaluated after the initiation of DAA treatment. HBV reactivation was defined as the presence of HBV DNA level ≥LLOD in patients with baseline HBV DNA level <LLOD, or increase of HBV DNA level >1 log 10 IU/mL in patients with baseline HBV DNA level ≥LLOD
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. HBV-associated hepatitis was defined as HBV reactivation and hepatitis flare presenting with ALT increase ≥3 times baseline and >100 U/L 
Results
Patient characteristics. Of 593 HCV-infected patients receiving SOF-based IFN-free DAAs, 76 were excluded from the study because of prior DAA exposure, eGFR < 30 mL/min/1.73 m 2 , receiving antiviral regimens not recommended by guidelines, or refusal to provide informed consent. The remaining 517 patients were eligible for the analysis (Fig. 1) . Table 1 shows the baseline patient characteristics. Thirty-four (6.6%), 139 (26.9%), 124 (24.0%) and 220 (42.6%) patients receiving SOF in combination with RBV, LDV, DCV and VEL, respectively. Patients receiving SOF/VEL tended to be younger, have a higher percentage of HIV-coinfected patients and a lower percentage of cirrhosis, compared to those receiving other SOF-based regimens. Among patients receiving SOF in combination with NS5A inhibitor, those receiving SOF/LDV tended to have a higher percentage of combining RBV usage, compared to those receiving SOF/DCV or SOF/VEL. All patients receiving SOF/RBV were infected with HCV genotype 2 (HCV-2) and were treated for 12 weeks, whereas all receiving SOF/LDV were infected with HCV-1a, HCV-1b or HCV-6. Sixty-nine (55.6%), one (0.8%), two (1.6%) and two (1.6%) receiving SOF/DCV had HCV-2, HCV-3, HCV-6, and mixed HCV genotype 1b + 2 and 2 + 6 infections. had undetectable serum HCV RNA levels at week 4 of treatment and at the end-of-treatment. One Child-Pugh C cirrhotic patient receiving SOF/LDV plus RBV died at treatment day 12 and the HCV RNA level at treatment week 1 was 1,047 IU/mL. The overall SVR 12 Table 2) .
Among patients who failed to achieved SVR 12 , 15 (2.9%) were relapsers and 9 (1.7%) were lost to follow-up. Among the 15 relapsers, 7 (46.7%) were male, 9 (60%) were treatment-naïve, and 10 (66.7%) had cirrhosis. Eight of the 9 (88.9%) patients who were lost to follow-up had HCV RNA level < LLOD at the last visit (Table 3) .
Among the 41 decompensated cirrhotic patients with available baseline and end of follow-up data, 32 (78%) and 9 (22%) of them had baseline Child-Pugh B and C. At the end of follow-up, 27 (66%), 12 (29%) and 2 (5%) of them had Child-Pugh A, B, and C, respectively ( Fig. 2A) . Regarding the scores for model for end-stage liver disease (MELD), 8 (20%), 3 (7%) and 30 (73%) of them had worsened, stable, and improved scores at the end of follow-up, as compared to the baseline status (Fig. 2B ).
Stratified analysis of baseline characteristics predictive of SVR 12 . Table 4 shows the stratified SVR 12 rates of SOF-based DAA regimens by baseline characteristics and week 4 treatment response. The SVR 12 rates were comparable with regard to age at a cut-off value of 55 years, sex, prior IFN exposure, HBV or HIV coinfection, prior history of HCC, scheduled 12 or 24 weeks of treatment, use of RBV, BMI at a cut-off value of 25 kg/m 2 , ALT quotient at a cut-off of 2, eGFR at a cut-off value of 60 mL/min/1.73 m 2 , baseline HCV viral load at a cut-off value of 6,000,000 IU/mL, HCV genotype, cirrhosis and week 4 viral decline in patients receiving SOF-based regimens. The SVR 12 rates for compensated cirrhotic and decompensated cirrhotic patients were 95.5% (95% CI: 84.9-98.7%) and 80.0% (95% CI: 58. 4 Safety. Five hundred fourteen of 517 (99.4%) patients completed the scheduled treatment. One Child-Pugh C and one Child-Pugh B cirrhotic patients receiving SOF/LDV plus RBV died at treatment day 12 and week 11 due to spontaneous bacterial peritonitis, respectively. One Child-Pugh A cirrhotic patient receiving SOF/VEL declined treatment after week 8 and another 6 patients declined off-therapy follow-ups. The reasons for lost to follow-up in the 7 patients were not related to DAA treatment (Table 3) . Among the 41 HCV-infected patients with HBV coinfection, 9 (22.0%) also had HIV coinfection. All the 9 patients received tenofovir (TDF)-based antiretroviral agents (ARTs) and none had baseline detectable serum HBV DNA level or had HBV reactivation after DAA treatment. Nineteen of 32 (59.4%) HBV/HCV-coinfected patients without HIV infection had baseline undetectable serum HBV DNA level; 13 (40.6%) had detectable serum HBV DNA levels (range: 25 to 1,820 IU/ mL). All the 32 patients did not receive oral nucleos(t)ide analogues or peginterferon for HBV prior to DAA treatment. Eighteen (56.3%) patients met the virologic criteria for HBV reactivation after the initiation of DAA treatment. One (3.1%) patient receiving SOF/LDV developed HBV-associated hepatitis at week 8 of treatment. The baseline HBV DNA level was 1,540 IU/mL, which peaked to 54,200 IU/mL at week 8 of treatment. The ALT level was 192 U/L and the serum HCV RNA level was <LLOD at the time of HBV reactivation. No concomitant serum total bilirubin level elevation or signs of hepatic decompensation was present. The patient received entecavir at week 9 and the ALT level normalized after 7 weeks of treatment. Table 3 . Summary of patients who failed to achieve SVR 12 . GT: genotype, Tx: treatment, LTFU: lost-to follow-up, SBP: spontaneous bacterial peritonitis. 
Discussion
Compared to PI-containing HCV DAA regimens such as paritaprevir/ritonavir, ombitasvir plus dasabuvir (PrOD), elbasvir/grazoprevir (EBR/GZR), or daclatasvir/asunaprevir (DCV/ASV), PI-free SOF-based regimens have relatively lower pill burden, broader genotype/subtype coverage, fewer drug-drug interactions (DDIs), and can be applied to patients with decompensated cirrhosis [11] [12] [13] [14] [15] [16] [17] [18] [19] 39 . Although the newly developed glecaprevir/pibrentasvir (GLE/PIB) and voxilaprevir (VOX)/SOF/VEL are potent regimens with pangenotypic activity, they are contraindicated for decompensated cirrhotic patients. Therefore, PI-free SOF-based regimens are appealing choices to health care providers for treating HCV infection.
Our study showed that the overall SVR 12 rate in patients receiving generic SOF in combination with RBV or NS5A inhibitors was excellent (95.4%) and was comparable to the response rates in patients receiving brand-name agents [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . The per-protocol SVR 12 rate was 97.1% after excluding patients with non-virologic failure. Regarding safety, >99% of our patients completed the scheduled treatment. Only 2 decompensated cirrhotic patients prematurely discontinued treatment due to spontaneous bacterial peritonitis, which were considered not related to DAA usage.
In our patients receiving SOF/RBV, all were infected with HCV-2, which reflected the potential suboptimal response rates in patients infected with other genotypes. The SVR 12 rate for SOF/RBV in our study was 85.3%, which was comparable to the response rates in clinical trials 12, 13 . Although there were no statistical differences for SVR 12 rates by baseline patient characteristics, our data were in line with VALENCE study that the CIs of the response rates varied widely, probably due to the small case numbers in both studies 13 . In HCV-2 cirrhotic patients receiving SOF/RBV for 12 weeks, the SVR 12 rates in FUSION and VALENCE trials as well as Western real-world practice were 60-82% 12, 13, 40 . However, the SVR 12 rate in our HCV-2 cirrhotic patients was higher (88.2%) than Western reports and was comparable to the response rates in East-Asian trials [41] [42] [43] . The factors attributed to the superior response rates in East-Asian patients to Western patients are still unknown. Furthermore, whether extending the treatment to 16 weeks could achieve better response rates in our HCV-2 cirrhotic patients needs further evaluation 12, 44 . The SVR 12 rate of our patients receiving generic SOF/LDV-based therapies was 93.5%, which was comparable to the response rates in patients receiving brand-name agents [14] [15] [16] [17] . Further analysis showed that our patients had similar SVR 12 rates to the phase II and III clinical trials by cirrhosis or genotype/subtype status [14] [15] [16] [17] 45 . Furthermore, the SVR 12 rates in our patients receiving SOF/LDV-based therapy were comparable irrespective of baseline patient characteristics, implying the use of generic SOF/LDV can also achieve excellent effectiveness.
About 66.5% of our patients were treated by generic SOF/DCV or SOF/VEL, probably due to the pangenotypic potency and relatively low pill burden compared to SOF/RBV or SOF/LDV 46 . The SVR 12 rates in our patients receiving generic SOF/DCV and SOF/VEL-based therapies were excellent and were comparable to the phase III clinical trials and real-world reports [18] [19] [20] [21] 47 . Of 23 decompensated cirrhotic patients receiving generic SOF/DCV or SOF/VEL with RBV for 12 weeks, or SOF/DCV or SOF/VEL without RBV for 24 weeks, all achieved SVR 12 , indicating these agents still had good therapeutic effects in critically ill patients. Furthermore, the response rates remained excellent in patients with unfavorable baseline characteristics. Our data indicated that generic SOF/ DCV or SOF/VEL also had similar effectiveness to brand-name agents.
Regarding our 43 decompensated cirrhotic patients, 39 (90.7%) of them achieved SVR 12 by generic SOF-based DAA therapies. Most patients had improving Child-Pugh class and MELD scores following treatment, implying that the mortality and morbidity can potentially be reduced in these very sick patients.
Among our 32 HBV/HCV coinfected patients not receiving antiviral agents for HBV, the risk of HBV reactivation and the HBV-related hepatitis after generic SOF-based therapies were similar to a recent prospective cohort enrolling 101 HBV/HCV coinfected patients receiving brand-name SOF/LDV, indicating that applying generic DAAs may not increase the risk of HBV reactivation and its associated complication 48 . However, watchful surveillance of HBV activity is still needed to detect and treat HBV-related hepatitis and hepatic decompensation earlier.
Our data showed that the rates of HCV RNA level < LLOD at week 4 of treatment were 88.2-90.3% in patients receiving SOF-based regimens. Although about 10% of our patients remained viremic at week 4 of treatment, the SVR 12 rates were comparable to those who were aviremic at week 4 of treatment. Therefore, the early virokinetics plays a minor role in predicting SVR 12 in patients receiving generic SOF-based therapies 49, 50 . Furthermore, our data was also in accordance with a recent meta-analysis that the SVR 12 rates of SOF-based therapies were comparable in Asian patients with or without history of HCC 51 . In addition to the excellent safety profiles and effectiveness, the prices of generic SOF-based DAA therapies are about 1-2% of the brand-name agents 52 . Based on these advantages, the use of generic SOF-based IFN-free DAA regimens may facilitate the mass treatment and play an important role in the elimination of HCV infection in the world, particularly in resource-constrained countries 53 . However, prudential assessment of severity of hepatic fibrosis, particularly for hepatic decompensation, and HCV genotype are still needed to optimize the treatment strategies.
Although generic SOF-based IFN-free DAAs had excellent safety and effectiveness, several limitations existed in our study. First, we included patients with different characteristics and the direct comparison of effectiveness and safety for each SOF-based regimen was not feasible. Second, the generic DAAs were made by various pharmaceutical companies and the direct comparison of effectiveness and safety was difficult. Third, data regarding the on-treatment constitutional or laboratory adverse events were not available in our retrospective study, making the detailed safety analysis impossible.
In summary, generic SOF-based IFN-free regimens achieved comparably excellent effectiveness and safety to the brand-name agents. These regimens may improve the care of HCV for patients with limited access to the expensive brand-name agents.
